Sulforaphane has not been proven to prevent dementia or treat Alzheimer's disease, according to the National Institute on Aging. Existing human studies provide reasons for further research, but they cannot show that it delays dementia or changes who develops it. Sulforaphane is a plant compound produced from glucoraphanin, which occurs in cruciferous plants. The most relevant long-term trial tested glucoraphanin with an ingredient intended to improve that conversion—not sulforaphane as a dementia treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the long-term pilot test?
- Did memory performance improve?
- What does the other human research add?
- Why can't these findings prove dementia prevention?
- What should readers do with this evidence?
What did the long-term pilot test?
A 2026 Japanese pilot enrolled 26 adults aged 63 to 90 who had memory impairment but did not have dementia. Participants received either placebo or 30 milligrams of glucoraphanin daily with mustard-derived myrosinase for 42 months. Myrosinase helps convert glucoraphanin into sulforaphane.
This formulation matters because its results cannot automatically be applied to broccoli foods or commercial products with different ingredients and conversion rates. Only 19 people completed follow-up: 10 in the glucoraphanin group and nine in the placebo group. That leaves considerable room for chance, individual differences, and participant dropout to influence the findings.
Did memory performance improve?
The overall pattern of memory-performance scores over time favored glucoraphanin, with a group-by-time result of p=0.012. However, the difference at the 42-month endpoint was only marginal, at p=0.079, as reported in the Frontiers in Nutrition pilot study. That distinction is important.
The scores followed different patterns during the study, but the final measurement did not provide clear evidence of a benefit. The trial also found no significant difference in movement between normal cognition and mild cognitive impairment. It therefore did not demonstrate that glucoraphanin prevented dementia, stopped progression, or restored normal cognition.
What does the other human research add?
A separate 12-week randomized trial studied 144 healthy older adults, not people with dementia. Sulforaphane improved processing speed and reduced negative mood compared with placebo, according to Frontiers in Aging Neuroscience. Those results may indicate a limited cognitive or mood effect in healthy participants.
They do not establish treatment of Alzheimer's disease or prevention of dementia. The same trial found no significant changes in measured markers of oxidative stress, inflammation, or neural plasticity. It therefore did not confirm those biological pathways as the reason for the reported performance differences.
Why can't these findings prove dementia prevention?
The strongest limitation is the mismatch between the question and the people studied. The long-term pilot involved adults with memory impairment but no dementia, while the shorter trial involved healthy older adults.
Other limits also narrow what readers can conclude: Industry involvement does not by itself invalidate a study. It does make independent replication especially important before using the results to guide dementia care.
- The long-term study began with 26 participants and ended with 19 completers.
- Its final memory endpoint did not reach definitive significance.
- It found no significant difference in cognitive-category conversion or reversion.
- It lacked the larger sample, biomarkers, and objective outcomes its authors said future trials need.
- Kagome funded the pilot, supplied the supplements, and participated in its design, analysis, and interpretation; three authors were employees.
What should readers do with this evidence?
Treat sulforaphane as an unproven research candidate, not an established dementia therapy. A public U.S.
registry describes a planned 160-participant, 24-week placebo-controlled study in prodromal-to-mild Alzheimer's disease, but a ClinicalTrials.gov registration does not establish efficacy or provide published outcomes. If you are considering a supplement: The clearest unresolved question is whether a defined sulforaphane-producing formulation can improve meaningful outcomes in a large, independent trial involving people with Alzheimer's disease.
- Do not substitute it for an existing dementia evaluation or care plan.
- Show the exact product label and dose to a clinician or pharmacist.
- Check whether the label lists sulforaphane, glucoraphanin, myrosinase, or a combination.
- Do not assume a broccoli serving or another supplement reproduces the studied formulation.
- Be skeptical of claims that memory-test changes prove Alzheimer's prevention.
